Xeris Biopharma Holdings (XERS) Cash Flow: Operating & Free Cash Flow

Xeris Biopharma Holdings Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Xeris Biopharma Holdings, Inc. (XERS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	0.55	-54.84	-62.26	-94.66	-122.73	-91.14	-91.14	-60.08	-26.55
Depreciation & Amortization	12.69	12.63	13.16	12.24	1.88	1.47	1.47	0.32	0.18
Deferred Income Tax	0.00	-2.27	-1.25	-1.42	0.00	0.00	0.54	-0.41	0.00
Stock Based Compensation	22.37	18.36	10.72	12.16	11.38	8.27	6.48	1.73	0.50
Change in Working Capital	-10.36	-8.82	-6.29	-35.15	11.85	-2.80	-2.80	1.61	1.12
Change in Accounts Receivable	-10.64	-1.22	-8.37	-13.37	-6.24	-2.18	-2.18	-1.67	-1.10
Change in Inventory	-19.29	-8.78	-14.80	-7.47	-7.42	-5.14	-5.14	4.04	1.70
Change in Accounts Payable	-0.07	-9.61	6.96	-4.32	5.53	-2.49	-2.49	-1.11	0.66
Change in Other Working Capital	3.37	-1.30	-2.68	1.39	19.98	7.01	7.01	0.35	-0.14
Other Operating Activities	3.37	-1.30	-2.68	2.52	2.08	3.64	4.89	0.56	0.09
Net Cash from Operating Activities	28.63	-36.98	-47.02	-102.89	-95.54	-80.56	-80.56	-56.28	-24.66
Investing Activities
Capital Expenditures	-0.70	-0.87	-2.26	-0.52	-1.09	-0.38	-0.38	-1.51	-0.70
Acquisitions	0.00	0.00	0.00	0.00	38.47	0.00	0.38	0.00	0.00
Purchases of Investments	0.00	-34.49	-43.74	34.99	-43.02	-101.77	-101.77	-68.85	0.00
Sales/Maturities of Investments	0.00	40.24	40.00	34.99	103.60	74.75	74.75	2.10	0.00
Other Investing Activities	0.00	0.00	0.00	0.00	0.00	0.00	-0.38	-66.75	0.00
Net Cash from Investing Activities	-0.70	4.88	-6.00	34.46	97.96	-27.41	-27.41	-68.26	-0.70
Financing Activities
Debt Repayment	9.17	-11.83	0.00	-43.50	0.00	69.75	25.00	35.00	0.00
Common Stock Issued	9.17	1.73	0.58	30.84	27.84	65.89	61.69	98.33	0.16
Common Stock Repurchased	-10.88	-3.73	-1.01	-0.47	-0.53	-0.06	0.00	0.00	0.00
Other Financing Activities	0.00	-11.83	-1.19	-5.61	-0.05	-9.51	101.06	4.11	35.14
Net Cash from Financing Activities	11.39	36.17	-1.61	127.47	27.25	126.06	126.06	128.21	35.14
Summary
Effect of Forex Changes on Cash	0.00	0.00	0.00	0.00	0.00	-0.02	-0.02	0.00	0.00
Net Change in Cash	39.32	4.07	-54.64	59.04	29.67	18.08	18.08	3.67	9.78
Cash at Beginning of Period	75.74	71.67	126.31	67.27	37.60	19.52	19.52	42.05	32.27
Cash at End of Period	115.06	75.74	71.67	126.31	67.27	37.60	37.60	45.72	42.05
Free Cash Flow	27.93	-37.85	-49.29	-103.42	-96.62	-80.94	-80.94	-57.79	-25.36
Supplemental Disclosures
Interest Paid	-	26.95	27.69	10.86	7.29	4.56	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xeris Biopharma Holdings Cash Flow

What is Xeris Biopharma Holdings's free cash flow?

Xeris Biopharma Holdings generated free cash flow of $27.93M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $28.63M minus $696.00K of capital expenditures. Free cash flow equaled 9.6% of revenue.

How much does Xeris Biopharma Holdings spend on capital expenditures?

Xeris Biopharma Holdings spent $696.00K on capital expenditures in fiscal 2025, compared with $868.00K a year earlier. That equals 2.4% of operating cash flow.

Does Xeris Biopharma Holdings pay dividends or buy back shares?

Yes. In fiscal 2025 Xeris Biopharma Holdings returned $10.88M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition